前收市價 | 9.39 |
開市 | 9.29 |
買盤 | 8.86 x 0 |
賣出價 | 8.87 x 0 |
今日波幅 | 8.65 - 9.44 |
52 週波幅 | 3.84 - 15.50 |
成交量 | |
平均成交量 | 2,165,899 |
市值 | 484.855M |
Beta 值 (5 年,每月) | 2.65 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -79.20 |
業績公佈日 | 2024年6月12日 - 2024年6月17日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 7.83 |
For cannabis stock investors, April ended in absolute euphoria. The sector has skyrocketed this week. The rally came on reports that the U.S. Drug Enforcement Agency (DEA) is set to reclassify marijuana’s controlled substance status. Marijuana is currently in Schedule 1, which is the strictest level of regulatory enforcement. This planned reclassification would move marijuana from Schedule 1, alongside drugs like LSD, to Schedule 3, where less serious drugs such as ketamine and anabolic steroids
Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.